BKYI · BIO-key International, Inc.
AI read · Neutral
The AI's read
BIO-key reported Q2 with a 13% revenue rise, a 51% improvement in net loss, 87% gross margin, and $2.5M raised via a warrant transaction. Management pointed to EMEA partnerships and Central Bank of Jordan opportunities. The market disagreed hard. The stock is down -11.14% since the call and RSI sits at 30.77, so sellers pushed first. Numbers and narrative clash. We lean neutral until recurring license revenue shows up and dilution/execution risks clear.